fda - Page 1 | CARLAT PUBLISHING

Clinical Update

Brexpiprazole’s New Claims

January 28, 2026

Kate Travis, MD. Attending Psychiatrist, Houston Methodist, Department of Psychiatry and Behavioral Health. Volunteer Adjunct Assistant Professor, University of Texas Health Science Center at Houston, Department of Psychiatry and Behavioral Sciences.

Dr. Travis has no financial relationships with companies related to this material.

Brexpiprazole’s uses are expanding beyond its original indications, with new research exploring its role in dementia and PTSD.

ProLivRx: How it Works

January 26, 2026

Chris Aiken, MD and Kellie Newsome, PMHNP

How a new FDA approved device for difficult-to-treat depression engages the brain through the sensory nerves in part II of our interview with Linda Carpenter.

ProLivRx: A New Approval in Depression

January 19, 2026

Chris Aiken, MD and Kellie Newsome, PMHNP

We interview Linda Carpenter, lead investigator on the new FDA approved device for difficult-to-treat depression.

PTSD 101: Prazosin or SSRI?

September 17, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

Should we follow the FDA and give SSRIs, or venture off-label with the fabled prazosin?

MDMA: What Went Wrong Part 2

June 17, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

Did boundary violations sink MDMA-assisted therapy, or was there something more? In part II of our series, we look at what else went wrong.

MDMA: What Went Wrong Part 1

June 10, 2024

Chris Aiken, MD

Did boundary violations sink MDMA assisted psychotherapy? We explore the reasons behind the FDA panel’s rejection of this psychedelic therapy.

Clinical Update

Off-Label Strategies for Common Psychiatric Conditions

June 1, 2024

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken has no financial relationships with companies related to this material.

Five disorders where going off-label has advantages over the FDA-approved route.

Research Update

Efficacy of Auvelity for Major Depression

April 1, 2024

Nina Chandler, DNP, APRN, PMHNP-BC

Nina Chandler, DNP, APRN, PMHNP-BC. Dr. Chandler has no financial relationships with companies related to this material.

A dextromethorphan-bupropion combo tablet shows promise in treating major depression. The FDA recognized its potential in 2019, so stay tuned for more updates on this novel treatment.

Clinical Update

Six Recent Disappointments in Psychiatric Research

February 1, 2024

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken has no financial relationships with companies related to this material.

Find out where standard therapies like cariprazine and esketamine have failed in recent trials, along with novel medications like minocycline, zuranolone, pimavanserin, and NAC.